Retrospective study on HER-2 low expression associated factors and efficacy on neoadjuvant chemotherapy
Yang Ziguo
You Han
Zhu Qiang
Wang Lin
Yin Ziyi
Wang Pilin
Wang Wenyan
Abstract：Objective To explore the clinicopathological characteristics and response to neoadjuvant chemotherapy of human epidermal growth factor receptor 2(HER-2)low breast cancer.Methods One hundred and nine HER-2 negative breast cancer were enrolled in our cohort for analysis,who were diagnosed in the Department of Breast Surgery,Beijing Tiantan Hospital affiliated to Capital Medical University from August 2019 to April 2023 and received neoadjuvant chemotherapy.Results The pathological complete response(pCR)rate of breast cancer with HER-2 low expression was 7.6％,lower than those with progesterone receptor(PR)positive(26.7％,p=0.008).Among HER-2 negative breast cancer,HER-2 low expression was associated with estrogen receptor(ER)positive(P=0.010),PR positive(P＜0.001),and Ki-67＜30％(P=0.002).Conclusion Among HER-2 negative breast cancer,HER-2 low expression is closely related to ER,PR status,Ki-67 level and neoadjuvant chemotherapy efficacy.
Keywords：HER-2 lowBreast cancerNeoadjuvant chemotherapyClinicopathological characteristics
Publication Date：2024-08-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 491-494 )